Alexandra N. Nowbar
National Institutes of Health
Internal medicineSurgeryCardiologyRandomized controlled trialHemodynamicsPlaceboStatinCoronary artery diseaseAnginaStenosisHypertrophic cardiomyopathyPercutaneous coronary interventionStress EchocardiographyTransplantationConventional PCIClinical trialIschemiaMedicineBlood pressureMeta-analysis
39Publications
11H-index
662Citations
Publications 37
Newest
#1James P. Howard (NIH: National Institutes of Health)H-Index: 23
#2Frances A. Wood (NIH: National Institutes of Health)H-Index: 1
Last. Chris Stride (University of Sheffield)H-Index: 34
view all 15 authors...
Abstract Background Most people who begin statins abandon them, most commonly because of side effects. Objectives The purpose of this study was to assess daily symptom scores on statin, placebo, an...
1 CitationsSource
#1Christopher Rajkumar (NIH: National Institutes of Health)H-Index: 7
Last. Thomas R. KeebleH-Index: 12
view all 14 authors...
Background: Retrievable stents and aspiration catheters have been developed to provide more effective arterial recanalisation in acute ischaemic stroke. Aims: The aim of this analysis was to test the effect of mechanical thrombectomy on mortality and longterm neurological outcome in patients presenting with acute large-vessel anterior circulation ischaemic stroke. Methods: A structured search identified randomised controlled trials of thrombectomy (using a retrievable stent or aspiration cathete...
Source
#1Alexandra N. Nowbar (NIH: National Institutes of Health)H-Index: 11
#2Darrel P. Francis (NIH: National Institutes of Health)H-Index: 88
Last. Rasha Al-Lamee (NIH: National Institutes of Health)H-Index: 24
view all 3 authors...
The main aims of therapy in chronic stable angina are to reduce the risk of myocardial infarction and death and improve symptoms and quality of life (QoL). Unblinded trials have shown that revascularization does not reduce the risk of myocardial infarction or death but does appear to improve symptoms. However, symptoms are susceptible to the placebo effect which can bias therapies to appear more effective than they are. To assess the true physical impact of a treatment on symptoms, placebo-contr...
Source
#1Henry Seligman (NIH: National Institutes of Health)H-Index: 5
#2Sukhjinder NijjerH-Index: 26
Last. Takayuki WarisawaH-Index: 7
view all 28 authors...
BACKGROUND Coronary blood flow in humans is known to be predominantly diastolic. Small studies in animals and humans suggest this is less pronounced or even reversed in the right coronary artery. AIMS This study aims to characterise the phasic patterns of coronary flow in the left versus right coronary arteries of patients undergoing invasive physiological assessment. METHODS We analysed data from the Iberian-Dutch-English Collaborators (IDEAL) Study. 482 simultaneous pressure and flow measureme...
Source
#1Christopher Rajkumar (NIH: National Institutes of Health)H-Index: 7
#2Matthew J. Shun-Shin (NIH: National Institutes of Health)H-Index: 24
Last. Caitlin Khan (NIH: National Institutes of Health)
view all 32 authors...
Background null Physiological assessment with pressure wire pullback can characterize coronary artery disease (CAD) with a focal or diffuse pattern. However, the clinical relevance of this distinction is unknown. We use data from the ORBITA trial (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) to test if the pattern of CAD predicts the placebo-controlled efficacy of percutaneous coronary intervention (PCI) on stress echocardiography ische...
1 CitationsSource
#1Alexandra N. Nowbar (NIH: National Institutes of Health)H-Index: 11
#2Christopher Rajkumar (NIH: National Institutes of Health)H-Index: 7
Last. Darrel P Francis (Hammersmith Hospital)
view all 4 authors...
ABSTRACT Recent randomised controlled trials, such as ISCHEMIA and ORBITA, have overturned most of what we were taught in medical school about hospital procedures considered necessary for patients with stable coronary artery disease. In this article, we discuss what these trials mean for physicians and patients considering revascularisation procedures with the hope of reducing the risk of death or alleviating angina.
Source
#1Victoria McCreanor (QUT: Queensland University of Technology)H-Index: 4
#2Alexandra N. Nowbar (Imperial College Healthcare)H-Index: 11
Last. William A. Parsonage (QUT: Queensland University of Technology)H-Index: 31
view all 10 authors...
Objective To evaluate the cost-effectiveness of percutaneous coronary intervention (PCI) compared with placebo in patients with single-vessel coronary artery disease and angina despite anti-anginal therapy. Design A cost-effectiveness analysis comparing PCI with placebo. A Markov model was used to measure incremental cost-effectiveness, in cost per quality-adjusted life-years (QALYs) gained, over 12 months. Health utility weights were estimated using responses to the EuroQol 5-level questionnair...
Source
Introduction: Improvement in exercise capacity is a therapeutic goal of percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD). Cardiopulmonary exercise testing (CPET) pr...
Source
Introduction: Cardiopulmonary exercise testing (CPET) provides a non-invasive evaluation of exercise physiology via ventilatory gas exchange (VGE). We do not know how these assessments correlate wi...
Source
#1Frances A. Wood (Imperial College London)H-Index: 1
#2James P. Howard (Imperial College London)H-Index: 23
Last. Darrel P. Francis (Imperial College London)H-Index: 88
view all 15 authors...
N-of-1 Trial of a Statin, Placebo, or No Treatment Patients who had discontinued statins because of side effects received four bottles of a statin, four bottles of placebo, and four empty bottles, ...
50 CitationsSource